Tuba ERÜRKER ÖZTÜRK, Murat KIYICI, Macit GÜLTEN, Enver DOLAR, Selim GÜREL, Selim GİRAY NAK, Fatih EREN

Importance of using tissue PCR to diagnose CMV colitis in ulcerative colitis

Objective: To show the importance of tissue Cytomegalovirus (CMV) PCR to diagnose CMV infection in patients with treatment-resistant ulcerative colitis. Methods: Fifteen patients who had previously been diagnosed as ulcerative colitis with clinical, endoscopic, histological, and radiological criteria and who had referred to our clinic with acute exacerbation who were diagnosed with CMV colitis and received CMV treatment, were evaluated retrospectively. After the demographic and clinical characteristics of the patients were noted, Mayo scores were evaluated to determine ulcerative colitis activity. Patients' age, gender, laboratory values, type of colitis, and Mayo scores were recorded. Biopsy results, CMV IgM, serum, and tissue CMV DNA levels were noted. Descriptive statistical parameters of the demographical data were calculated. Results: Eleven of the patients were male, and four were female. The mean age of the patients was 42±11,3. The mean duration of the disease was 28±46 months. Twelve patients had pancolitis, and three patients had distal colitis. All patients' Mayo score was 12 points. All patients were steroid-resistant, and none had previously received biological agent therapy. 7 of 15 patients had serum CMV DNA levels over 1000 copies/mL. Tissue CMV DNA levels of 8 patients were found higher than 250 copies/mg, although serum CMV DNA levels were below 1000 copies/mL. Pathology samples of 11 patients were evaluated, and CMV inclusion bodies were not detected. All patients received ganciclovir for CMV treatment. After treatment, CMV DNA of all patients was negative, and diarrhea and inflammation markers were reduced. Conclusion: For the diagnosis of CMV, CMV-PCR in colon tissue specimens should also be considered in addition to endoscopic appearance and serum CMV DNA levels.

Keywords:

CMV DNA, PCR, Ulcerative colitis, CMV colitis, Cytomegalovirus,

PDF

___

1.Staras SA, Dollard SC, Radford KW, et al.Seroprevalence of cytomegalovirus infection in theUnited States, 1988-1994. Clin Infect Dis 2006; 43:1143-51.
2.Papadakis KA, Tung JK, Binder SW, et al. Outcomeof cytomegalovirus infections in patients withinflammatory bowel disease. Am J Gastroenterol 2001; 96: 2137-42.
3. Odze RD, Goldblum JR. Surgical pathology of the GI tract, liver, biliary tract, and pancreas. 2nd ed.Philadelphia: W.B. Saunders/Elsevier, 2009; 52-53.
4.Carter D, Olchovsky D, Pokroy R, Ezra D.Cytomegalovirus-associated colitis causing diarrheain an immunocompetent patient. World JGastroenterol 2006; 12: 6898-9.
5.Iida T, Ikeya K, Watanabe F, et al. Looking forendoscopic features of cytomegalovirus colitis: astudy of 187 patients with active ulcerative colitis,positive and negative for cytomegalovirus. InflammBowel Dis 2013; 19: 1156-63.
6.Omiya M, Matsushita M, Tanaka T, Kawamata s,Okazaki K. The absence of large ulcer predicts latentcytomegalovirus infection in ulcerative colitis withpositive mucosal viral assay. Intern Med 2010; 49:2277-82.
7.Suzuki H, Kato J, Kuriyama M, et al. Specificendoscopic features of ulcerative colitis complicated by cytomegalovirus infection. World J Gastroenterol2010; 16: 1245-51.
8.Rahier JF, Magro F, Abreu C, et al. SecondEuropean evidence-based consensus on theprevention, diagnosis and management ofopportunistic infections in inflammatory boweldisease. J Crohns Colitis 2014; 8: 443-68.
9.Storch GA, Buller RS, Bailey TC, et al. Comparisonof PCR and pp65 antigenemia assay withquantitative shell vial culture for detection ofcytomegalovirus in blood leukocytes from solid-organ transplant recipients. J Clin Microbiol 1994;32: 997-1003.
10.Roblin X, Pillet S, Oussalah A, et al.Cytomegalovirus load in inflamed intestinal tissue ispredictive of resistance to immunosuppressivetherapy in ulcerative colitis. Am J Gastroenterol2011; 106: 2001-8.
11.Sager K, Alam S, Bond A, Chinnappan L, ProbertCS. Review article: cytomegalovirus andinflammatory bowel disease. Aliment PharmacolTher 2015; 41: 725-33.
12.Wilks S, Moxon W. Lectures on pathologicalanatomy. London: Longmans, Green, 1889.
13.Powell RD, Warner NE, Levine RS, Kirsner JB.Cytomegalic inclusion disease and ulcerative colitis;report of a case in a young adult. Am J Med 1961; 30:334-40.
14.Lawlor G, Moss AC. Cytomegalovirus ininflammatory bowel disease: pathogen or innocentbystander? Inflamm Bowel Dis 2010; 16: 1620-7.
15.Kim YS, Kim YH, Kim JS, et al. Cytomegalovirusinfection in patients with new onset ulcerativecolitis: a prospective study. Hepatogastroenterology2012; 59: 1098-01.
16.Cotte L, Drouet E, Bissuel F, Denoyel A, Trepo C.Diagnostic value of amplification of humancytomegalovirus DNA from gastrointestinal biopsies from human immunodeficiency virus-infectedpatients. J Clin Microbiol 1993; 31: 2066-9.
17.Hommes DW, Sterringa G, van Deventer SJ,Tytgat GNJ, Weel J. The pathogenicity ofcytomegalovirus in inflammatory bowel disease: asystematic review and evidence-basedrecommendations for future research. InflammBowel Dis 2004; 10: 245-50.
18.Kandiel A, Lashner B. Cytomegalovirus colitiscomplicating inflammatory bowel disease. Am JGastroenterol 2006; 101: 2857-65.
19.Kou T, Nakase H, Tamaki H, et al.Cytomegalovirus infection in patients withulcerative colitis diagnosed by quantitative real-time PCR analysis. Dig Dis Sci 2006; 51: 1052-5.
20.Rahbar A, Bostrom L, Lagerstedt U, et al.Evidence of active cytomegalovirus infection andincreased production of IL-6 in tissue specimensobtained from patients with inflammatory boweldiseases. Inflamm Bowel Dis 2003; 9: 154-161.
21.Robey SS, Gage WR, Kuhajda FP. Comparison ofimmunoperoxidase and DNA in situ hybridizationtechniques in the diagnosis of cytomegaloviruscolitis. Am J Clin Pathol 1988; 89: 666-71.
22. Wakefield AJ, Fox JD, Sawyerr AM, et al. Detection of herpesvirus DNA in the large intestine of patientswith ulcerative colitis and Crohn's disease using the nested polymerase chain reaction. J Med Virol 1992; 38: 183-90.
23.Garrido E, Carrera E, Manzano R, Lopez-Sanroman A. Clinical significance ofcytomegalovirus infection in patients withinflammatory bowel disease. World J Gastroenterol2013; 19: 17-25.
24.Ormeci AC, Akyuz F, Baran B, et al. Steroid-refractory inflammatory bowel disease is a riskfactor for CMV infection. Eur Rev Med Pharmacol Sci2016; 20: 858-65.
25.Landry ML, Ferguson D. Comparison ofquantitative cytomegalovirus antigenemia assaywith culture methods and correlation with clinicaldisease. J Clin Microbiol 1993; 31: 2851-6.
26.Göral V. Endoscopic Features of UlcerativeColitis. Türkiye Klinikleri J. Gastroenterohepatol-Special Topics 2009; 2 (1):34-40.
27.Kelle İ, Erdinç M. General Features of AntiviralDrugs. Erdinç M, editör. Viral EnfeksiyonlardaGüncel Tedavi Yaklaşımları ve İmmünizasyon. 1.Baskı. Ankara: Türkiye Klinikleri; 2021. p.8-30.
28.Beswick L, Ye B and van Langenberg D. Towardan Algorithm for the Diagnosis and Management ofCMV in Patients with Colitis. Inflamm Bowel Dis2016;22:2966–76.
29.Mourad FH, Hashash JG, Kariyawasam VJ, LeongRW. Ulcerative Colitis and CytomegalovirusInfection: From A to Z. Journal of Crohn's and Colitis, 2020, 1162–71.
30.Goetgebuer RL, van der Woude CD, Bakker L, etal. The diagnosis and management of CMV colitis inIBD patients shows high practice variation: anational survey among gastroenterologists. Scand JGastroenterol 2022 Nov; 57(11):1321-1326.
31.Kwon J, Flux D, Farraye FA, Kröner PT.Cytomegalovirus‑related colitis in patients withinflammatory bowel disease. Int J Colorectal Dis.2022 Mar; 37(3): 685-691.